{
    "name": "Monoclonal Antibody",
    "alt_names": [
        "Casirivimab/Imdevimab",
        "REGEN-COV"
    ],
    "class": [
        "Monoclonal Antibody"
    ],
    "indications": [
        "Adult or pediatric (>12 years of age and weighing at least 40 kg) + not vaccinated/immunosuppressed + exposed to an individual with SARS-COV2/high risk of exposure to"
    ],
    "contraindications": [
        "Hospitalization due to COVID-19",
        "On oxygen therapy"
    ],
    "side_effects": [],
    "routes": [
        "{IV}",
        "{SQ}"
    ],
    "dose": {
        "general": [
            "Use adult dosage for all patients >12 years of age and weighing at least 40 kg"
        ],
        "pedi": [
            "Not indicated for patients < 12 yoa and < 40kg. Greater than use adult dosage."
        ],
        "adult": [
            "{IV} Casirivimab 600 mg and Imdevimab 600 mg in 100mL NS - Infuse IV piggyback in a NS line at KVO  over 21 minutes (310 mL/hr) Infuse through NS primed micron filter 0.20 or 0.22 size",
            "{SQ} Casirivimab 600 mg (2.5 mL) in 2 separate syringes and Imdevimab 600 mg (2.5 mL) in 2 separate syringes Administer 4 SQ injections in separate muscle areas. Avoid the waistline and 5 cm periumbilically"
        ]
    },
    "protocols": [
        "[SC5]"
    ],
    "pearls": [
        "For treatment of symptomatic COVID-19, the intravenous route is preferred under the EUA, but if there would be a delay in providing IV administration, subcutaneous administration is acceptable."
    ]
}